News Quantified

ALIM – alimera sciences, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences [Yahoo! Finance]

Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Alimera Sciences, Inc. (NASDAQ:ALIM): When Will It Breakeven? [Yahoo! Finance]

Alimera Sciences: Deal Closing After All, CVR Still Attractive [Seeking Alpha]

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

0.7%

MISS

-5.7%

MISS

0.8%

MISS

Form 4 ALIMERA SCIENCES INC For: Sep 16 Filed by: Velan Capital Management LLC

Form SC 13D/A ALIMERA SCIENCES INC Filed by: Velan Capital Investment Management LP

Form S-8 POS ALIMERA SCIENCES INC

Form S-8 POS ALIMERA SCIENCES INC

Form S-8 POS ALIMERA SCIENCES INC

Top News Gainers

3/25 Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference 26.0%

11/13 Alimera Sciences Terminates Equity Purchase Agreement 19.8%

4/13 Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update 18.1%

2/26 Q4/2019 12/31/2019 EPS 0.080 ZacksConsensus -0.370 ActVsEst 0.450 - Beat 14.7%

9/11 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 12.9%

3/31 Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement 10.8%

11/8 Form 8-K ALIMERA SCIENCES INC For: Nov 07 10.5%

11/14 Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split 9.0%

11/15 Alimera Sciences Inc (NASDAQ: ALIM) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 8.3%

10/14 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.0%

Top News Decliners

7/29 Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update -31.6%

7/30 Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -23.8%

3/11 Form 4 ALIMERA SCIENCES INC For: Mar 09 Filed by: Kaba Samer -23.1%

6/20 Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis -16.4%

11/13 Form 8-K ALIMERA SCIENCES INC For: Nov 12 -16.1%

3/18 Form SEC STAFF LETTER ALIMERA SCIENCES INC -14.3%

10/1 Alimera Sciences Inc (NASDAQ: ALIM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -13.7%

10/1 Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting -13.5%

11/7 Form 8-K/A ALIMERA SCIENCES INC For: Nov 04 -12.7%

9/3 Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication -11.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day